Squarepoint
RUBY

Squarepoint’s Rubius Therapeutics, Inc RUBY Stock Holding History

Squarepoint’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-162,657
Closed -$138K – 3622
2022
Q2 		$138K Buy
+162,657
New +$273K ﹤0.01% 2571
2022
Q1 		– Sell
-43,117
Closed -$417K – 3779
2021
Q4 		$417K Buy
+43,117
New +$598K ﹤0.01% 2262
2021
Q3 		– Sell
-17,500
Closed -$427K – 3647
2021
Q2 		$427K Buy
17,500
+2,025
+13% +$50.7K ﹤0.01% 2258
2021
Q1 		$410K Sell
15,475
-5,980
-28% -$87.3K ﹤0.01% 2169
2020
Q4 		$163K Sell
21,455
-32,255
-60% -$192K ﹤0.01% 2592
2020
Q3 		$269K Buy
53,710
+24,308
+83% +$129K ﹤0.01% 1883
2020
Q2 		$176K Buy
+29,402
New +$174K ﹤0.01% 1861

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Squarepoint's RUBY Position: Q3 2022 in Review

Squarepoint sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2022, closing a stake of 162,657 shares — an estimated $138K sold.

Squarepoint first reported a position in RUBY in Q2 2020 and held it in 7 quarters. The position peaked at $427K in Q2 2021. 62 funds tracked by Wall St. Rank hold RUBY as of Q3 2022.

  • Squarepoint reported no remaining Rubius Therapeutics, Inc position as of Q3 2022 after selling out during the quarter.
  • Squarepoint sold 162,657 Rubius Therapeutics, Inc shares in Q3 2022, an estimated $138K.
  • Squarepoint first reported a position in Rubius Therapeutics, Inc in Q2 2020 and held it in 7 quarters.
  • Squarepoint's Rubius Therapeutics, Inc position peaked at $427K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2022.

Based on Squarepoint's 13F filing for Q3 2022, filed 14 Nov 2022.